<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812448462</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812448462</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Friedreich Ataxia Clinical Outcome Measures</article-title>
<subtitle>Natural History Evaluation in 410 Participants</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Regner</surname>
<given-names>Sean R.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilcox</surname>
<given-names>Nicholas S.</given-names>
</name>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Friedman</surname>
<given-names>Lisa S.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seyer</surname>
<given-names>Lauren A.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schadt</surname>
<given-names>Kim A.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brigatti</surname>
<given-names>Karlla W.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perlman</surname>
<given-names>Susan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0883073812448462">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Delatycki</surname>
<given-names>Martin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0883073812448462">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilmot</surname>
<given-names>George R.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff6-0883073812448462">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gomez</surname>
<given-names>Christopher M.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff7-0883073812448462">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bushara</surname>
<given-names>Khalaf O.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff8-0883073812448462">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mathews</surname>
<given-names>Katherine D.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff9-0883073812448462">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Subramony</surname>
<given-names>S. H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff10-0883073812448462">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ashizawa</surname>
<given-names>Tetsuo</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff10-0883073812448462">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ravina</surname>
<given-names>Bernard</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff11-0883073812448462">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brocht</surname>
<given-names>Alicia</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff11-0883073812448462">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Farmer</surname>
<given-names>Jennifer M.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
<xref ref-type="aff" rid="aff12-0883073812448462">12</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lynch</surname>
<given-names>David R.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0883073812448462">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448462">2</xref>
<xref ref-type="aff" rid="aff3-0883073812448462">3</xref>
<xref ref-type="corresp" rid="corresp1-0883073812448462"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073812448462"><label>1</label>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA</aff>
<aff id="aff2-0883073812448462"><label>2</label>Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA</aff>
<aff id="aff3-0883073812448462"><label>3</label>Children’s Hospital of Philadelphia, Philadelphia, PA, USA</aff>
<aff id="aff4-0883073812448462"><label>4</label>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA</aff>
<aff id="aff5-0883073812448462"><label>5</label>Murdoch Children’s Research Institute, Melbourne, Victoria, Australia</aff>
<aff id="aff6-0883073812448462"><label>6</label>Department of Neurology, Emory University, Atlanta, GA, USA</aff>
<aff id="aff7-0883073812448462"><label>7</label>Department of Neurology, University of Chicago, Chicago, IL, USA</aff>
<aff id="aff8-0883073812448462"><label>8</label>Department of Neurology, University of Minnesota, Minneapolis, MN, USA</aff>
<aff id="aff9-0883073812448462"><label>9</label>Departments of Neurology and Pediatrics, University of Iowa, Iowa City, IA, USA</aff>
<aff id="aff10-0883073812448462"><label>10</label>Department of Neurology, University of Florida, Gainesville, FL, USA</aff>
<aff id="aff11-0883073812448462"><label>11</label>Department of Neurology, University of Rochester, Rochester, NY, USA</aff>
<aff id="aff12-0883073812448462"><label>12</label>Friedreich Ataxia Research Alliance, Downingtown, PA, USA</aff>
<contrib-group content-type="issue">
<contrib contrib-type="editor">
<name>
<surname>Maria</surname>
<given-names>Bernard L.</given-names>
</name>
<degrees>MD, MBA</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0883073812448462">David R. Lynch, MD, PhD, Department of Neurology, University of Pennsylvania School of Medicine, 3615 Civic Center Blvd, ARC Ste 502, Philadelphia, PA 19104, USA Email: <email>lynchd@mail.med.upenn.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>9</issue>
<issue-title>Special Issue: Childhood Ataxia</issue-title>
<fpage>1152</fpage>
<lpage>1158</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia, dysarthria, and areflexia. The authors report the progress of a large international noninterventional cohort (n = 410), tracking the natural history of disease progression using the neurologic examination-based Friedreich Ataxia Rating Scale. The authors analyzed the rate of progression with cross-sectional analysis and longitudinal analysis over a 2-year period. The Friedreich Ataxia Rating Scale captured disease progression when used at 1 and 2 years following initial evaluation, with a lower ratio of standard deviation of change to mean change over 2 years of evaluation. However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached.</p>
</abstract>
<kwd-group>
<kwd>Friedreich ataxia</kwd>
<kwd>natural history study</kwd>
<kwd>noninterventional study</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Friedreich ataxia is an autosomal recessive disorder caused by mutations in the gene <italic>FXN</italic>.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812448462">1</xref>
</sup> Of people with the disorder, 97% have an expanded GAA triplet repeat in both alleles, whereas the remaining 3% of subjects carry an expanded GAA repeat on 1 allele and a point mutation on the other.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448462">2</xref>
</sup> The length of the shorter GAA repeat correlates with age of onset (<italic>r</italic> = 0.6-0.7).<sup>
<xref ref-type="bibr" rid="bibr3-0883073812448462">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073812448462">4</xref>
</sup> The repeat is in the first intron, and its expansion leads to decreased messenger RNA transcription and a deficiency of the protein frataxin.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812448462">1</xref>
</sup> Similarly, point mutations in <italic>FXN</italic> lead to absence of functional frataxin.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448462">2</xref>,<xref ref-type="bibr" rid="bibr5-0883073812448462">5</xref>
</sup>
</p>
<p>Neurological manifestations of Friedreich ataxia are progressive and include, loss of coordination, dysarthria, and extensor plantar responses. Subjects can also have scoliosis, cardiomyopathy, diabetes, pes cavus, bladder dysfunction, optic atrophy, and hypoacusis.<sup>
<xref ref-type="bibr" rid="bibr6-0883073812448462">6</xref>
<xref ref-type="bibr" rid="bibr7-0883073812448462"/>–<xref ref-type="bibr" rid="bibr8-0883073812448462">8</xref>
</sup> Onset typically occurs in late childhood or early adolescence, but can be as late as the seventh decade of life.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812448462">9</xref>
<xref ref-type="bibr" rid="bibr10-0883073812448462"/>–<xref ref-type="bibr" rid="bibr11-0883073812448462">11</xref>
</sup> At present, there is no approved treatment in the United States, although several clinical trials have been conducted in the past 5 years.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812448462">12</xref>
<xref ref-type="bibr" rid="bibr13-0883073812448462"/>
<xref ref-type="bibr" rid="bibr14-0883073812448462"/>
<xref ref-type="bibr" rid="bibr15-0883073812448462"/>–<xref ref-type="bibr" rid="bibr16-0883073812448462">16</xref>
</sup>
</p>
<p>Investigational drug trials in Friedreich ataxia have been aided by the presence of several ongoing natural history studies that have assessed the rate of change in Friedreich ataxia with quantifiable measures.<sup>
<xref ref-type="bibr" rid="bibr17-0883073812448462">17</xref>,<xref ref-type="bibr" rid="bibr18-0883073812448462">18</xref>
</sup> Measures used for quantitation of neurological function include the neurologic examination-based Friedreich Ataxia Rating Scale,<sup>
<xref ref-type="bibr" rid="bibr17-0883073812448462">17</xref>
</sup> which has been used as an outcome measure in several clinical trials.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812448462">12</xref>,<xref ref-type="bibr" rid="bibr19-0883073812448462">19</xref>,<xref ref-type="bibr" rid="bibr20-0883073812448462">20</xref>
</sup> As previously shown in modest-sized cross-sectional analysis and in longitudinal analysis after 2 years of follow-up, the scale captures disease progression in Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448462">4</xref>,<xref ref-type="bibr" rid="bibr9-0883073812448462">9</xref>
</sup> This study provides interim analysis of the average rates of change over 2 years in an expanded cohort of subjects with Friedreich ataxia from the American/Australian natural history study, using the Friedreich Ataxia Rating Scale examination.</p>
<sec id="section1-0883073812448462" sec-type="methods">
<title>Method</title>
<p>This study had the approval of each site’s Institutional Review Board, and participants provided written informed consent before enrolling. The cross-sectional cohort of individuals (n = 410) with genetically confirmed Friedreich ataxia was examined at 1 of 9 institutions: Children’s Hospital of Philadelphia and the University of Pennsylvania (156 participants), University of California, Los Angeles (95 participants), Murdoch Children’s Research Institute (66 participants), Emory University (52 participants), University of Minnesota (18 participants), University of Iowa (11 participants), University of Chicago (8 participants), and University of Rochester (4 participants). All participants with a follow-up visit at year 1 or 2 from baseline were included in longitudinal analysis. This is an actively enrolling study and some participants were not yet in the window for year 1 or 2 visits. For transition analysis, visits beyond the first 2 years (out through year 6) were also used. Interim reports on smaller versions of this cohort have appeared previously.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448462">4</xref>,<xref ref-type="bibr" rid="bibr9-0883073812448462">9</xref>
</sup>
</p>
<p>Longitudinal analysis was performed on 251 participants who returned for their 1 year after baseline (V01) or 2 years after baseline (V02) examinations. Of those who returned, we calculated the change from baseline to year 1 and year 2, as well as the yearly rate of change in the Friedreich Ataxia Rating Scale,<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448462">4</xref>,<xref ref-type="bibr" rid="bibr9-0883073812448462">9</xref>
</sup> performed as described previously. Data analysis was performed using Stata 11.2 software (StataCorp, College Station, Texas.) using regression models, correlations, transition charts, and analysis of variance (ANOVA). Clinical and demographic information were obtained at the baseline visits and included age of symptom onset, length of GAA repeats, age at examination, and sex.</p>
<p>In some analyses the population was stratified to examine progression rates for subpopulations. Subpopulations were created by stratifying for length of the shorter GAA repeat (≤ 300, &gt; 300-600, &gt; 600), sex, age (&lt; 18 or ≥ 18), and Friedreich Ataxia Rating Scale score (&lt; 70 or ≥ 70).</p>
<p>To analyze ceiling and floor effects, annual changes in Friedreich Ataxia Rating Scale score were assessed at different Friedreich Ataxia Rating Scale ranges. Each examination was categorized into a particular range and analyzed chronologically for transitions between ranges. Friedreich Ataxia Rating Scale ranges were set equal to 10 points, giving a total of 12 divisions (with the top division ending at the maximum Friedreich Ataxia Rating Scale score of 117). The 10-point range was selected after reviewing progression rates from previous manuscripts. If the yearly Friedreich Ataxia Rating Scale change resulted in a transition to a higher Friedreich Ataxia Rating Scale range, the change was recorded as an increase. The transition probability for each range was then calculated as the number of individuals progressing to the next range divided by the number of individuals originally in the range. A minority of subjects (6%) made Friedreich Ataxia Rating Scale transitions between nonadjacent Friedreich Ataxia Rating Scale ranges; these were excluded from the initial analysis. If subjects had Friedreich Ataxia Rating Scale scores in the decimal range between 2 ranges, then all scores greater than 0.5 were rounded up to the higher range. To account for the effect of reverse transitions, the transition probabilities for reverse Friedreich Ataxia Rating Scale transitions were calculated as the negative of the number of reverse transitions divided by number of individuals in the original range. This ensured that the reverse directionality of the transition was accounted for. A weighted average of the forward and reverse transitions was taken. This analysis was performed for all subjects, as well as for individuals within each GAA repeat length subpopulation.</p>
</sec>
<sec id="section2-0883073812448462">
<title>Results</title>
<sec id="section3-0883073812448462">
<title>Cohort Features</title>
<p>From our cross-sectional cohort of 410 participants with Friedreich ataxia, 259 (63%) returned for follow-up visits over the next 6 years after baseline. When we adjusted for the fact that some participants who enrolled later in the study were not yet within the time frame for V01 when data analysis occurred, the return rate was 79% overall at 1 to 6 years, with return rates of 69% at V01 and 64% at V02. The average length of GAA repeats in the shorter allele was 662 ± 247. There were 15 subjects with point mutations (1 A460T, 1 G130V, 1 I154F, 1 L106S, 1 L182F, 1 W154R, 1 R165C, 1 DelA+3 Intron 4, 1 splice site mutation, 6 unidentified). The average age of onset for the cohort was 13.7 years. The cross-sectional cohort had an average Functional Disability Score<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448462">4</xref>
</sup> of 3.5 and a Friedreich Ataxia Rating Scale score of 63.7, which is equivalent to a person walking with moderate to severe ataxia. To ensure there was no selection bias in the subjects who returned for follow-up, we compared the clinical and demographic features of the cross-sectional and longitudinal cohorts at each year. The groups were similar in sex, age of onset, and testing site (data not shown). The longitudinal cohort was predominantly adult (69.4%).</p>
</sec>
<sec id="section4-0883073812448462">
<title>Cross-Sectional Analysis of Friedreich Ataxia Rating Scale Scores</title>
<p>To analyze factors influencing Friedreich Ataxia Rating Scale examination scores, we initially performed cross-sectional analysis over the entire cohort using multivariate regression. Scores were predicted by age and length of the shorter GAA repeat, while sex and examination site did not predict scores (<xref ref-type="table" rid="table1-0883073812448462">Table 1</xref>). When displayed graphically as function of duration, there was a clear difference among participants with different GAA repeat lengths (<xref ref-type="fig" rid="fig1-0883073812448462">Figure 1</xref>). There was substantial variability with Friedreich Ataxia Rating Scale score as a function of duration in subjects with GAA repeats of 300 or less (<italic>r</italic> = 0.56). In individuals with intermediate-length repeats (300 to 600), the Friedreich Ataxia Rating Scale score generally was linear with duration (<italic>r</italic> = 0.81). However, in participants with long GAA repeats, the relationship became nonlinear at longer durations (<italic>r</italic> = 0.70), suggesting that participants reach the ceiling of the scale (<xref ref-type="fig" rid="fig1-0883073812448462">Figure 1</xref>).</p>
<fig id="fig1-0883073812448462" position="float">
<label>Figure 1.</label>
<caption>
<p>Change in Friedreich Ataxia Rating Scale (FARS) score with disease duration+measured in years. FARS shown as function of disease duration in the subpopulations based on GAA repeat length &gt; 600 (A), &gt; 300-600 (B), and ≤ 300 (C).</p>
</caption>
<graphic xlink:href="10.1177_0883073812448462-fig1.tif"/>
</fig>
<table-wrap id="table1-0883073812448462" position="float">
<label>Table 1.</label>
<caption>
<p>Cross-Sectional Analysis of FARS Scores</p>
</caption>
<graphic alternate-form-of="table1-0883073812448462" xlink:href="10.1177_0883073812448462-table1.tif"/>
<table>
<thead>
<tr>
<th>Measure</th>
<th>GAA</th>
<th>Coeff</th>
<th>Sex</th>
<th>Coeff</th>
<th>Age</th>
<th>Coeff</th>
<th>Overall</th>
<th>Overall <italic>R</italic>
<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448462">2</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>FARS</td>
<td>&lt;0.001</td>
<td>.0484</td>
<td>0.496</td>
<td>–1.30</td>
<td>&lt;0.001</td>
<td>.797</td>
<td>&lt;0.001</td>
<td>.356</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812448462">
<p>Linear regression was used to examine the effect of GAA repeat length, age, and sex on baseline FARS scores. Significance values for each variable are listed under GAA, sex, and age. Site was included as a dummy variable and did not predict FARS (data not shown). The total number of participants with complete information was 353. Abbreviations: Coeff, regression coefficient; FARS, Friedreich Ataxia Rating Scale; GAA, triplet repeat; sig, significance.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0883073812448462">
<title>Longitudinal Analysis</title>
<p>We then analyzed the observed progression rates over 2 years. The Friedreich Ataxia Rating Scale captured disease progression as demonstrated by scores at year 1 and 2 that were significantly different than baseline, with a substantially better ratio of standard deviation of change to mean change at year 2 compared with year 1 (<xref ref-type="table" rid="table2-0883073812448462">Table 2</xref>). Still, the ratio was relatively high for use in a nonstratified clinical trial; consequently, we examined rates of change in subpopulations. Children progressed over twice as fast as measured by the Friedreich Ataxia Rating Scale over 1 year (<xref ref-type="table" rid="table3-0883073812448462">Table 3</xref>). Progression was perhaps slightly faster in female participants (<xref ref-type="table" rid="table3-0883073812448462">Table 3</xref>). We also stratified results by GAA repeat length. For participants with GAA repeat lengths less than 300, the Friedreich Ataxia Rating Scale change was only moderately significant within the 2-year period, reflecting not a lack of change but a high variability in the rate of change. Progression rates for the intermediate and long GAA repeat groups were faster, with greater ratios of standard deviation of change to mean change. In addition, change was slower in participants with Friedreich Ataxia Rating Scale scores greater than 70.</p>
<table-wrap id="table2-0883073812448462" position="float">
<label>Table 2.</label>
<caption>
<p>Change in FARS Examination Stratified by Year to Baseline</p>
</caption>
<graphic alternate-form-of="table2-0883073812448462" xlink:href="10.1177_0883073812448462-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="3">Baseline to Year 1</th>
<th colspan="3">Baseline to Year 2</th>
<th colspan="3">All Observations</th>
</tr>
<tr>
<th>FARS</th>
<th>Sig</th>
<th align="center">Mean ± SD (FARS U/year)</th>
<th>N</th>
<th>Sig</th>
<th align="center">Mean ± SD (FARS U/year)</th>
<th>N</th>
<th>Sig</th>
<th align="center">Mean ± SD (FARS U/year)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>
</td>
<td>0.000</td>
<td>2.66 ± 7.14</td>
<td>249</td>
<td>0.000</td>
<td>6.20 ± 10.7</td>
<td>249</td>
<td>0.000</td>
<td>2.89 ± 4.27</td>
<td>251</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0883073812448462">
<p>The yearly change in FARS scores were determined by regression analysis for change from baseline to year 1, change from baseline to year 2, and using all observations. Abbreviations: FARS, Friedreich Ataxia Rating Scale; SD, standard deviation; sig, significance.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0883073812448462" position="float">
<label>Table 3.</label>
<caption>
<p>Analysis of Change in FARS Scores by Subpopulations</p>
</caption>
<graphic alternate-form-of="table3-0883073812448462" xlink:href="10.1177_0883073812448462-table3.tif"/>
<table>
<tbody>
<tr>
<th>Stratification</th>
<th colspan="9">
</th>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="3">Adult</td>
<td align="center" colspan="3">Pediatric</td>
<td colspan="3">
</td>
</tr>
<tr>
<td>Age</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>&lt; .001</td>
<td>2.02 ± 4.02</td>
<td>176</td>
<td>&lt; .001</td>
<td>4.71 ± 5.46</td>
<td>91</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="3">GAA ≤ 300</td>
<td align="center" colspan="3">GAA &gt; 300 and ≤ 600</td>
<td align="center" colspan="3">GAA &gt; 600</td>
</tr>
<tr>
<td>GAA</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
</tr>
<tr>
<td>
</td>
<td>0.038</td>
<td>1.58 ± 4.14</td>
<td>24</td>
<td>&lt; .001</td>
<td>2.63 ± 3.58</td>
<td>79</td>
<td>0.000</td>
<td>3.41 ± 4.41</td>
<td>128</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="3">Female</td>
<td align="center" colspan="3">Male</td>
<td colspan="3">
</td>
</tr>
<tr>
<td>Sex</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>&lt; .001</td>
<td>3.09 ± 4.27</td>
<td>129</td>
<td>&lt; .001</td>
<td>2.70 ± 4.27</td>
<td>122</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="3">FARS ≤ 70</td>
<td align="center" colspan="3">FARS &gt; 70</td>
<td colspan="3">
</td>
</tr>
<tr>
<td>FARS Score</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td align="center">Sig</td>
<td align="center">Mean ± SD (FARS U/year)</td>
<td align="center">N</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>&lt; .001</td>
<td>2.88 ± 4.72</td>
<td>158</td>
<td>&lt; .001</td>
<td> 1.76 ± 4.19</td>
<td>117</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0883073812448462">
<p>The change in FARS scores was analyzed when stratified based on clinical/demographic features. Abbreviations: FARS, Friedreich Ataxia Rating Scale; GAA, triplet repeat; SD, standard deviation; sig, significance.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>To further explore the apparent ceiling effects of the Friedreich Ataxia Rating Scale, transition probability analysis was performed. Based on transition analysis, the relative amount of Friedreich Ataxia Rating Scale score change decreased as the score increased (<xref ref-type="fig" rid="fig2-0883073812448462">Figure 2</xref>). For the entire cohort the transition probability decreased from 0.4 at a baseline Friedreich Ataxia Rating Scale score of 30 to 39 to a negative transition at a baseline of 100 to 109. It is interesting that this fall was relatively steep; the transition probability fell only slightly between baseline scores of 30 to 39 and 70 to 79, but fell rapidly with each subsequent transition group. However, when groups were stratified by GAA repeat length, the fall in transition probability seen between a baseline score of 30 to 39 and 50 to 59 was more obvious, as the subpopulation with the shortest GAA repeat length behaved differently. This group changed more slowly at low scores than the subjects with longer GAA repeats and never reached the ceiling of the scale. Overall, the differences based on GAA repeat length were modest.</p>
<fig id="fig2-0883073812448462" position="float">
<label>Figure 2.</label>
<caption>
<p>Friedreich Ataxia Rating Scale (FARS) score transition probabilities. FARS score transition probabilities are shown as function of FARS range. All observations are shown in panel A and are stratified by GAA repeat length in panel B.</p>
</caption>
<graphic xlink:href="10.1177_0883073812448462-fig2.tif"/>
</fig>
<p>However, in the transition probability analysis, we could not include the small number of transitions greater than 1 Friedreich Ataxia Rating Scale range. Since these subjectively appeared to occur more frequently in individuals with lower baseline scores, this exclusion might obscure floor effects. Consequently, we also looked at the mean change in score within each transition group (<xref ref-type="fig" rid="fig3-0883073812448462">Figure 3</xref>). Overall, the yearly change in score was relatively constant between baseline scores of 30 and 89, but then fell after that point. This confirms the presence of a significant ceiling effect on the Friedreich Ataxia Rating Scale, but a relatively consistent yearly change at scores below 89.</p>
<fig id="fig3-0883073812448462" position="float">
<label>Figure 3.</label>
<caption>
<p>Average Friedreich Ataxia Rating Scale (FARS) change in each FARS range. The average FARS change for participants at different FARS ranges is shown for all observations in panel A and stratified by GAA repeat length in panel B.</p>
</caption>
<graphic xlink:href="10.1177_0883073812448462-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section6-0883073812448462">
<title>Discussion</title>
<p>In this study we analyzed Friedreich Ataxia Rating Scale scores in a large heterogeneous cohort with cross-sectional analysis and longitudinal analysis of change over 2 years in a natural history study. As noted in our previous studies of a smaller group within this cohort, the ratio of standard deviation of change to mean change is much lower after 2 years of evaluation, suggesting that for unselected cohorts, 2 years may be the minimum needed for reasonable power in clinical trials. However, the data from stratifications show that younger participants or those with longer GAA repeat lengths change substantially faster than the overall cohort. This suggests that the population segments with these characteristics may be the best targets statistically for such trials. Subjects with short GAA repeats changed somewhat slower, but more impressively, this group showed a highly variable progression rate both when examined cross-sectionally and longitudinally. This variability may be useful in modifier gene analysis to allow assessment of non-<italic>FXN</italic>-mediated genetic variability in Friedreich ataxia.</p>
<p>The cross-sectional analysis and transition analysis both identified a substantial ceiling effect in the Friedreich Ataxia Rating Scale. The transition probability and the apparent rate of change slowed with scores greater than 89, but were relatively constant to that point. Conceptually, all scales with fixed endpoints (117 for the Friedreich Ataxia Rating Scale examination) must have ceiling effects (though they may not be apparent in a given cohort).<sup>
<xref ref-type="bibr" rid="bibr18-0883073812448462">18</xref>
</sup> The ability to statistically identify such ceilings depends on the size and composition of the cohort. However, the transition probability analysis defines the range in which ceiling effects begin to occur. It is interesting that in the participants with longest GAA repeats, an apparent ceiling appeared with time, which was not as apparent with participants with shorter repeat lengths. This emphasizes the more rapid change that occurs before they reach the ceiling of the Friedreich Ataxia Rating Scale. As noted before in the smaller version of this cohort, women appear to progress at a slightly faster rate. The reason for this is still unclear but has been noted in other cohorts.<sup>
<xref ref-type="bibr" rid="bibr21-0883073812448462">21</xref>
</sup> Overall, the present work emphasizes the validity of this instrument as well as its limitations and provides a framework for its use in future investigations.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors would like to thank the many subjects who participated in the study and the research coordinators at each site. This article is based on a presentation given at the Neurobiology of Disease in Children Symposium: Childhood Ataxia, in conjunction with the 40th Annual Meeting of the Child Neurology Society, Savannah, Georgia, October 26, 2011. We thank Melanie Fridl Ross, MSJ, ELS, for editing assistance. This work was performed by the authors at their own specific institutions, and at the University of Texas Medical Branch and the University of Mississippi, the former location for Dr Subramony.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812448462">
<label>Author Contributions</label>
<p>SRR, NSW, and DRL performed the data analysis and wrote the manuscript. LSF and AB provided statistical expertise. LAS, KAS, LSF, and KWB contributed to data acquisition, assessment, and critical revision of the work. SP, MD, GRW, CMG, KOB, SHS, TA, and KDM provided critical revision of the work and performed data acquisition. JMF and DRL designed the study.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812448462">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812448462">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was supported by grants from the Muscular Dystrophy Association and the Friedreich Ataxia Research Alliance. Supported by grants from the National Institutes of Health (2R13NS040925-14 Revised), the National Institutes of Health Office of Rare Diseases Research, the Child Neurology Society, and the National Ataxia Foundation.</p>
</fn>
<fn fn-type="other" id="fn4-0883073812448462">
<label>Ethical Approval</label>
<p>This study was approved by all participating IRBs. Participants provided written consent before participating.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812448462">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campuzano</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Montermini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Molto</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion</article-title>. <source>Science</source>. <year>1996</year>;<volume>271</volume>:<fpage>1423</fpage>–<lpage>1427</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812448462">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bidichandani</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Ashizawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>PI</given-names>
</name>
</person-group>. <article-title>Atypical Friedreich ataxia caused by compound heterozygosity for a novel Missense mutation and the GAA triplet-repeat expansion</article-title>. <source>Am J Hum Genet</source>. <year>1997</year>;<volume>60</volume>:<fpage>1251</fpage>–<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812448462">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical and genetic abnormalities in patients with Friedreich’s ataxia</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>335</volume>:<fpage>1169</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812448462">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Measuring Friedreich ataxia: complementary features of examination and performance measures</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>66</volume>:<fpage>1711</fpage>–<lpage>1716</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812448462">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>45</volume>:<fpage>200</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812448462">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Balcer</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia: Effects of genetic understanding on clinical evaluation and therapy</article-title>. <source>Arch Neurol</source>. <year>2002</year>;<volume>59</volume>:<fpage>743</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812448462">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>:<fpage>1296</fpage>–<lpage>1303</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812448462">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regner</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Lagedrost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Plappert</surname>
</name>
<etal/>
</person-group>. <article-title>Analysis of echocardiograms in a large heterogeneous cohort of patients with Friedreich ataxia</article-title>. <source>Am J Cardiol</source>. <year>2012</year>;<volume>109</volume>:<fpage>401</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812448462">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812448462">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Molecular pathogenesis of Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>1999</year>;<volume>56</volume>:<fpage>1201</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812448462">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimanis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Glutz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Very-late-onset Friedreich ataxia with disturbing head tremor and without spinal atrophy—case report</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>7</issue>):<fpage>1058</fpage>–<lpage>1059</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812448462">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2010</year>;<volume>67</volume>(<issue>8</issue>):<fpage>941</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812448462">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>13</issue>):<fpage>1940</fpage>–<lpage>1944</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812448462">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schöls</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zange</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abele</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>L-carnitine and creatine in Friedreich’s ataxia. A randomized, placebo-controlled crossover trial</article-title>. <source>J Neural Transm</source>. <year>2005</year>;<volume>112</volume>(<issue>6</issue>):<fpage>789</fpage>–<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812448462">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velasco-Sánchez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aracil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montero</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia</article-title>. <source>Cerebellum</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812448462">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsou</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Pharmacotherapy for Friedreich ataxia</article-title>. <source>CNS Drugs</source>. <year>2009</year>;<volume>23</volume>(<issue>3</issue>):<fpage>213</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812448462">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahey</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Corben</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2007</year>;<volume>78</volume>(<issue>4</issue>):<fpage>411</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812448462">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Figoni</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Annual change in Friedreich's ataxia evaluated by the scale for the assessment and rating of ataxia (SARA) is independent of disease severity</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>:<fpage>135</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812448462">
<label>19</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Willi</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<etal/>
</person-group>. <comment>EPI-A0001: new potential therapy for Friedreich ataxia. American Neurological Association; September 25-27, 2011; San Diego, Calif</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.aneuroa.org/files/2011%20Annual%20Meeting/ANA_Abstract%20Booklet_2011.pdf">http://www.aneuroa.org/files/2011%20Annual%20Meeting/ANA_Abstract%20Booklet_2011.pdf</ext-link>. <comment>Accessed</comment> .</citation>
</ref>
<ref id="bibr20-0883073812448462">
<label>20</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Zesiewicz</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Kamp</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Double-blind, randomize, placebo-controlled pilot study of varenicline (Chantix<sup>®</sup>) in the treatment of Friedreich’s ataxia</article-title>. <comment>American Academy of Neurology; April 9-16, 2011; Honolulu, Hawaii</comment>. <ext-link ext-link-type="uri" xlink:href="http://www.abstracts2view.com/aan/view.php?nu=AAN11L_IN7-1.001">http://www.abstracts2view.com/aan/view.php?nu=AAN11L_IN7-1.001</ext-link>. <comment>Accessed</comment>.</citation>
</ref>
<ref id="bibr21-0883073812448462">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klockgether</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ludtke</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>The natural history of degenerative ataxia: a retrospective study in 466 patients</article-title>. <source>Brain</source>. <year>1998</year>;<volume>121</volume>:<fpage>589</fpage>–<lpage>600</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>